MedGenome has launched OncoTrack MRD, a blood-based test designed to detect microscopic residual cancer cells. The product rollout is part of the company's broader expansion strategy in the Indian diagnostics market. Note that MedGenome is a private, unlisted company and does not trade on the NSE or BSE.
MedGenome has introduced OncoTrack MRD, a new diagnostic service focused on detecting residual cancer cells in patients with solid tumors such as breast, lung, and colorectal cancer. The test works by analyzing circulating tumor DNA (ctDNA) from blood samples to identify signs of potential cancer recurrence earlier than traditional imaging methods, such as CT or PET scans. This allows oncologists to potentially adjust treatment plans sooner based on longitudinal data rather than waiting for visible tumors to appear on scans.
This product launch is a key part of MedGenome’s ongoing business strategy to strengthen its position in the competitive Indian precision oncology and diagnostics market. The company has been pursuing an aggressive growth path, which has included inorganic acquisitions such as Prognosis Laboratories and Siddhi Diagnostics. By bringing specialized genomic testing services to the domestic market, the company aims to support the 'Make in India' initiative while expanding its infrastructure to reach a broader network of private hospitals.
For those tracking the sector, it is important to understand the company's business scale. In fiscal year 2025, MedGenome reported revenue in the range of ₹407 crore. As a private, unlisted entity, MedGenome does not have a ticker on the National Stock Exchange (NSE) or the Bombay Stock Exchange (BSE), and its shares are not available for public trading. Investors looking at the diagnostic space should note that while the demand for advanced genomics is rising, the sector is highly fragmented and features significant competition from both large national chains and smaller regional players.
The risks for the business primarily involve the operational complexity of scaling high-end genomic testing services nationwide. Maintaining high analytical sensitivity for residual disease detection requires robust logistics and sample handling capabilities. Additionally, the company must manage the integration of its recent diagnostic acquisitions and ensure they contribute positively to overall profitability. Regulatory compliance in the healthcare and diagnostics sector remains another critical factor that could affect future operations.
The next important monitorable for the business will be the adoption rate of the OncoTrack MRD test by large private oncology networks. Success will depend on the company’s ability to prove the clinical efficacy of the test to doctors and hospitals while managing costs during its continued phase of expansion and acquisition integration.